Brought to you by 
Bayer Korea divests contraceptives to Dong-A Pharmaceutical
03 Jan 2022
Executive Summary
Dong-A Pharmaceutical Co. Ltd. acquired four OTC contraceptives from Bayer Korea Ltd. The transaction included legal rights on Korean and English trademarks, manufacturing methods, production know-how, sales rights, and approval data.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer Korea divests contraceptives to Dong-A Pharmaceutical
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice